Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.

diffuse large b-cell lymphoma (dlbcl) germinal center b-cell-like (gcb) hans algorithm ki67 index proliferative index

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
04 Feb 2021
Historique:
entrez: 17 3 2021
pubmed: 18 3 2021
medline: 18 3 2021
Statut: epublish

Résumé

Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma. The 2016 World Health Organization (WHO) update on hematopoietic tumors suggested that all DLBCL cases should be subtyped into germinal and non-germinal center phenotypes. Ki67 immunohistochemistry is a maker of cell proliferation and thus is used as a prognostic and predictive marker in various tumors of human body. Only a few studies evaluated the proliferative index of DLBCL subtypes in our population. Therefore, in this study, we evaluated the frequency of subtypes of DLBCL in our population and K67 index in each subtype. Methods A retrospective observational study was conducted in the Department of Histopathology, Liaquat National Hospital and Medical College, from January 2018 till December 2020, over a period of three years. A total of 101 cases with a histopathological diagnosis consistent DLBCL were included in the study. Immunohistochemical (IHC) stains CD10, B-cell lymphoma 6 (Bcl-6), and multiple myeloma oncogene 1 (MUM1) were applied for the further sub-categorization of DLBCL into germinal center B-cell-like (GCB) and non-GCB subtypes according to the Hans algorithm. The Ki67 index was interpreted in hot spots of the tumor and reported as an average percentage. Results Out of 101 DLBCL cases, 47.5% of DLBCL were GCB, while 52.5% were non-GCB subtypes. Bcl-2, Bcl-6, MUM1, c-Myc, CD10, and CD30 expression were noted in 62.4%, 45.5%, 42.6%, 44.6%, 39.6%, and 7.9% cases, respectively. The mean Ki67 index was 72.94±16.69%. The mean Ki67 index in non-GCB-type DLBCL was 77.67±14.80%, which was significantly higher than the mean Ki67 index in GCB-type DLBCL (67.70±17.22%) with a significant p-value (p=0.002). Cervical lymph node was the most common site of DLBCL, while the stomach was the most common extra-nodal site. A significant association of Ki67 index was noted with subtypes of DLBCL. A higher proportion of non-GCB-type DLBCL exhibited greater than 80% Ki67 index than GCB subtype DLBCL. Moreover, a significant association Ki67 index was noted with c-Myc positivity. A higher proportion of c-Myc-positive DLBCL had greater than 80% Ki67 index. Conclusion We found that non-GCB-type DLBCL had a higher Ki67 index than GCB subtype DLBCL, portending a poor prognostic significance of non-GCB subtype of DLBCL. Moreover, c-Myc expression was associated with a higher Ki67 index.

Identifiants

pubmed: 33728138
doi: 10.7759/cureus.13120
pmc: PMC7936471
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e13120

Informations de copyright

Copyright © 2021, Hashmi et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cureus. 2021 Jan 11;13(1):e12640
pubmed: 33585126
BMC Cancer. 2014 Mar 05;14:153
pubmed: 24597851
Cureus. 2020 Nov 29;12(11):e11764
pubmed: 33409012
J Clin Oncol. 2012 Oct 1;30(28):3460-7
pubmed: 22665537
Cell Rep. 2018 Jul 31;24(5):1105-1112.e5
pubmed: 30067968
Ann Oncol. 2000;11 Suppl 1:3-10
pubmed: 10707771
Cancer. 2012 Sep 1;118(17):4173-83
pubmed: 22213394
J Clin Oncol. 2012 Oct 1;30(28):3452-9
pubmed: 22851565
Avicenna J Med. 2020 Oct 13;10(4):241-248
pubmed: 33437697
Eur J Haematol. 2012 Jun;88(6):510-7
pubmed: 22413767
Oncol Lett. 2017 Sep;14(3):3767-3773
pubmed: 28927145
Asian Pac J Cancer Prev. 2013;14(7):4353-8
pubmed: 23992002
Leuk Lymphoma. 2008 Aug;49(8):1501-9
pubmed: 18766962
Best Pract Res Clin Haematol. 2012 Mar;25(1):41-7
pubmed: 22409822
Semin Diagn Pathol. 2011 May;28(2):113-23
pubmed: 21842697
Ann Hematol. 2004 Jul;83(7):414-9
pubmed: 15085385
BMC Res Notes. 2019 Sep 23;12(1):605
pubmed: 31547858
Asian Pac J Cancer Prev. 2014;15(20):8759-63
pubmed: 25374203
Am J Hematol. 2019 May;94(5):604-616
pubmed: 30859597
Pathology. 2018 Jan;50(1):74-87
pubmed: 29167021

Auteurs

Atif A Hashmi (AA)

Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.

Syeda N Iftikhar (SN)

Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.

Gul Nargus (G)

Pathology, Khyber Medical University, Peshawar, PAK.

Omer Ahmed (O)

Internal Medicine, Liaquat National Hospital and Medical College, Karachi, PAK.

Ishaq Azeem Asghar (IA)

Pathology, Ascension St. John Hospital, Detroit, USA.

Umme Aiman Shirazi (UA)

Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.

Anoshia Afzal (A)

Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

Muhammad Irfan (M)

Statistics, Liaquat National Hospital and Medical College, Karachi, PAK.

Javaria Ali (J)

Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.

Classifications MeSH